C07K 16/2887
Against cd20
Official title: {against CD20}
C07K16/2887 (Against cd20) appears on 1,515 US grants and 3,309 published applications in this corpus.
Search patents in C07K- Granted patents
- 1,515
- Published applications
- 3,309
- Assignees
- 867
- Inventors
- 4,418
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 2 | 0 |
| 1998 | 6 | 0 |
| 1999 | 1 | 0 |
| 2000 | 3 | 0 |
| 2001 | 3 | 1 |
| 2002 | 4 | 15 |
| 2003 | 4 | 18 |
| 2004 | 2 | 12 |
| 2005 | 4 | 34 |
| 2006 | 4 | 40 |
| 2007 | 3 | 47 |
| 2008 | 14 | 44 |
| 2009 | 12 | 77 |
| 2010 | 25 | 68 |
| 2011 | 32 | 96 |
| 2012 | 42 | 88 |
| 2013 | 42 | 98 |
| 2014 | 63 | 190 |
| 2015 | 78 | 166 |
| 2016 | 85 | 188 |
| 2017 | 93 | 204 |
| 2018 | 87 | 160 |
| 2019 | 121 | 204 |
| 2020 | 110 | 196 |
| 2021 | 133 | 227 |
| 2022 | 104 | 247 |
| 2023 | 106 | 229 |
| 2024 | 120 | 267 |
| 2025 | 124 | 214 |
| 2026 | 87 | 179 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Bispecific chimeric antigen receptors targeting CD20 and BCMA6 Oct 2026US 12,751,973 B2Abelzeta Inc.
- Compositions and methods of treating lupus nephritis6 Oct 2026US 12,752,005 B2Genentech, Inc.
- Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof29 Sep 2026US 12,747,279 B2Abelzeta Inc.
- Methods and antibody compositions for tumor treatment29 Sep 2026US 12,747,300 B2Regeneron Pharmaceuticals, Inc.
- RNA encoding an antibody29 Sep 2026US 12,747,451 B2Cure Vac SE
- Targeted engineered interferon and uses thereof8 Oct 2026US 2026/0308221 A1Orionis Biosciences BV
- Multi-receptor natural killer cells8 Oct 2026US 2026/0308225 A1Board of Regents, The University of Texas System
- Methods of enhancing antibody therapies8 Oct 2026US 2026/0308270 A1Ohio State Innovation Foundation
- Immunotherapeutic proteins8 Oct 2026US 2026/0308271 A1Macfarlane Burnet Institute for Medical Research and Public Health Limited
- Lentiviral delivery of anti-cd20 chimeric antigen receptors8 Oct 2026US 2026/0308622 A1
Most cited
By later US patents
- Polypeptide variants with altered effector function1,378US 6,737,056 B1Genentech, Inc. · 2004
- Chimeric antibody with specificity to human B cell surface antigen853US 5,500,362 AXoma Corporation · 1996
- Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma744US 5,736,137 AIDEC Pharmaceuticals Corporation · 1998
- Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity604US 6,602,684 B1GlycArt Biotechnology AG · 2003
- Optimized Fc variants463US 7,317,091 B2Xencor, Inc. · 2008